Xtandi
China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer
November 6, 2020Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi
China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …
FDA approves Pfizer and Astellas Pharma’s prostate cancer drug
December 17, 2019Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer
The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
Pfizer receives prostate cancer drug boost with trial results
September 15, 2017Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi
March 30, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price
US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
Astellas in ‘unacceptable’ Xtandi ABPI code breach
July 3, 2015Medical Communications, Sales and Marketing ABPI Code, Astella, PMCPA, Xtandi
The industry code of conduct regulator has singled out Astellas for ‘particular censure’ for arranging a meeting for UK healthcare …
NICE rejects Otelza but SMC recommends it
June 11, 2015Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla
Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …
Mixed bag for Novartis and Astellas in breast cancer
December 15, 2014Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus
Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …
FDA approves new indication for Xtandi
September 11, 2014Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate
The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …
NICE ‘yes’ for cancer drugs
July 23, 2014Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy
Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …
NICE recommends Xtandi
May 9, 2014Sales and Marketing Astellas, NICE, Xtandi, abiraterone, prostate
NICE has reiterated that Astellas Pharma’s Xtandi should be used to treat NHS prostate cancer patients – but has removed …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
